Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASIPHAE
2016-002893-11Phase 2Terminated
- Sponsor
- Karolinska University Hospital
- Start
- Apr 2017
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib, fulvestrant, capecitabine and goserelin in breast cancer (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Progression-free survival. Started Apr 2017; status: terminated.
02
Drugs
palbociclibfulvestrantcapecitabinegoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-002893-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002893-11.